Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083717 | 0.89 | NPC1 (0.42) | NPC1RAB9AHSD17B10MEN1KMT2A | |
| SCHEMBL19075723 | 0.87 | NPC1 (0.43) | NPC1RAB9AHSD17B10MAPTPOLB | |
| SCHEMBL19083720 | 0.77 | LRRK2 (0.46) | NPC1HSD17B10MEN1KMT2ATHRB | |
| SCHEMBL19075715 | 0.76 | LRRK2 (0.47) | NPC1HSD17B10MEN1KMT2AMAPT | |
| SCHEMBL8292210 | 0.71 | CYP1A2 (0.56) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL8867311 | 0.71 | GABRP (0.44) | POLBACACBHTT | |
| SCHEMBL13662610 | 0.70 | HPGD (0.48) | MEN1KMT2AACACBSMN1; SMN2 | |
| SCHEMBL26225912 | 0.68 | HTT (0.46) | RAB9AHSD17B10THRBACACBKDM4E | |
| SCHEMBL30100610 | 0.68 | SMN1; SMN2 (0.58) | NPC1RAB9AHSD17B10MEN1KMT2A | |
| SCHEMBL8334790 | 0.67 | MMP13 (0.45) | NPC1RAB9AKMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | NPC1 1736/4885RAB9A 915/4885HSD17B10 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.